Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery

Biomaterials

Volumn 32, Issue 14, 2011, Pages 3666-3678

  Zhang, Zhiping ^a,b,c   Tongchusak, Songsak ^a,b   Mizukami, Yo ^a   Kang, Yoon Joong ^a,b   Ioji, Tetsuya ^d   Touma, Maki ^a,b   Reinhold, Bruce ^a,b   Keskin, Derin B ^a,b   Reinherz, Ellis L ^a,b   Sasada, Tetsuro ^a,b,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Immune escape; Interferon ; Nanoparticle; Peptide; Toll like receptor 4 agonist; Tumor immunity

Indexed keywords

ANTI-TUMOR ACTIVITIES; ANTI-TUMORS; ANTIGEN DELIVERY; ANTIGEN PRESENTATION; ANTIGENIC PEPTIDES; B16 MELANOMA; C57BL/6 MICE; CANCER IMMUNOTHERAPY; CLASS I; COMBINED TREATMENT; CYTOTOXIC; CYTOTOXIC T LYMPHOCYTES; DOUBLE EMULSIONS; ESCAPE MECHANISM; FLUORESCENT DYES; IMMUNE ESCAPE; IN-VITRO; INTRADERMAL INJECTION; LIPID A; MURINE DENDRITIC CELLS; POLY(D ,L-LACTIDE-CO- GLYCOLIDE); T-CELL RESPONSE; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 4 AGONIST; TUMOR CELLS; UP-REGULATION;

ANTIBIOTICS; ANTIGENS; DERMATOLOGY; EMULSIFICATION; GLYCOPROTEINS; INTERFERONS; NANOPARTICLES; ONCOLOGY; ORGANIC POLYMERS; PEPTIDES;

TUMORS;

FREUND ADJUVANT; GAMMA INTERFERON; HGP100 25-33; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PHOSPHORYL LIPID A; POLYGLACTIN; TRP2 180-188; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG UPTAKE; EMULSION; FEASIBILITY STUDY; LYMPHOCYTE PROLIFERATION; MELANOMA CELL; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; DENDRITIC CELLS; FLOW CYTOMETRY; LACTIC ACID; MASS SPECTROMETRY; MICE; NANOPARTICLES; PEPTIDES; POLYGLYCOLIC ACID; T-LYMPHOCYTES, CYTOTOXIC; TANDEM MASS SPECTROMETRY;

MURINAE; MUS;

EID: 79952106754     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.01.067     Document Type: Article

References (49)

1. Pulendran B., Ahmed R. Translating innate immunity into immunological memory: Implications for vaccine development. Cell 2006, 124:849-863.
2. Berzofsky J.A., Terabe M., Oh S., Belyakov I.M., Ahlers J.D., Janik J.E., et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004, 113:1515-1525.
3. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004, 10:909-915.
4. Finn O.J. Cancer immunology. N Engl J Med 2008, 358:2704-2715.
5. Purcell A.W., McCluskey J., Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007, 6:404-414.
6. O'Neill D.W., Adams S., Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004, 104:2235-2246.
7. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5:296-306.
8. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007, 117:1195-1203.
9. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
10. Reddy S.T., Swartz M.A., Hubbell J.A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 2006, 27:573-579.
11. Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7:790-802.
12. Langer R., Cleland J.L., Hanes J. New advances in microsphere-based single-dose vaccines. Adv Drug Deliv Rev 1997, 28:97-119.
13. Shen H., Ackerman A.L., Cody V., Giodini A., Hinson E.R., Cresswell P., et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006, 117:78-88.
14. Ferrari M., Downing G. Medical nanotechnology: Shortening clinical trials and regulatory pathways?. BioDrugs 2005, 19:203-210.
15. Almeida A.J., Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007, 59:478-490.
16. Vasir J.K., Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 2007, 59:718-728.
17. Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., Swartz M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 2006, 112:26-34.
18. Elamanchili P., Diwan M., Cao M., Samuel J. Characterization of poly(D, L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 2004, 22:2406-2412.
19. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 2007, 178:2979-2986.
20. Solbrig C.M., Saucier-Sawyer J.K., Cody V., Saltzman W.M., Hanlon D.J. Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells. Mol Pharm 2007, 4:47-57.
21. Yoshikawa T., Okada N., Oda A., Matsuo K., Matsuo K., Kayamuro H., et al. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells. Vaccine 2008, 26:1303-1313.
22. Hamdy S., Molavi O., Ma Z., Haddadi A., Alshamsan A., Gobti Z., et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 2008, 26:5046-5057.
23. Kwon Y.J., Standley S.M., Goh S.L., Frechet J.M. Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J Control Release 2005, 105:199-212.
24. Diwan M., Tafaghodi M., Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release 2002, 85:247-262.
25. de Jong S., Chikh G., Sekirov L., Raney S., Semple S., Klimuk S., et al. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol Immunother 2007, 56:1251-1264.
26. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26:1626-1637.
27. Chong C.S., Cao M., Wong W.W., Fischer K.P., Addison W.R., Kwon G.S., et al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release 2005, 102:85-99.
28. Bloom M.B., Perry-Lalley D., Robbins P.F., Li Y., el-Gamil M., Rosenberg S.A., et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997, 185:453-459.
29. Overwijk W.W., Tsung A., Irvine K.R., Parkhurst M.R., Goletz T.J., Tsung K., et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998, 188:277-286.
30. Zeh H.J., Perry-Lalley D., Dudley M.E., Rosenberg S.A., Yang J.C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999, 162:989-994.
31. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003, 198:569-580.
32. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223:77-92.
33. Riemer A.B., Keskin D.B., Zhang G., Handley M., Anderson K.S., Brusic V., et al. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J Biol Chem 2010, 285:29608-29622.
34. Reinhold B, Keskin DB, Reinherz EL. Molecular detection of targeted major histocompatibility complex i-bound peptides using a probabilistic measure and nanospray ms(3) on a hybrid quadrupole-linear ion trap. Anal Chem 2010, in press.
35. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995.
36. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376.
37. Jilek S., Ulrich M., Merkle H.P., Walter E. Composition and surface charge of DNA-loaded microparticles determine maturation and cytokine secretion in human dendritic cells. Pharm Res 2004, 21:1240-1247.
38. Yoshida M., Babensee J.E. Poly(lactic-co-glycolic acid) enhances maturation of human monocyte-derived dendritic cells. J Biomed Mater Res A 2004, 71:45-54.
39. Jerome V., Graser A., Muller R., Kontermann R.E., Konur A. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant. J Immunother 2006, 29:294-305.
40. Elamanchili P., Lutsiak C.M., Hamdy S., Diwan M., Samuel J. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J Immunother 2007, 30:378-395.
41. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
42. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404-1413.
43. Chang C.C., Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 2007, 56:227-236.
44. Merritt R.E., Yamada R.E., Crystal R.G., Korst R.J. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy. J Thorac Cardiovasc Surg 2004, 127:355-364.
45. Li B., Lei Z., Lichty B.D., Li D., Zhang G.M., Feng Z.H., et al. Autophagy facilitates major histocompatibility complex class I expression induced by IFN-gamma in B16 melanoma cells. Cancer Immunol Immunother 2010, 59:313-321.
46. Seliger B., Wollscheid U., Momburg F., Blankenstein T., Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001, 61:1095-1099.
47. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440:808-812.
48. Zhang J.X., Zhu K.J. An improvement of double emulsion technique for preparing bovine serum albumin-loaded PLGA microspheres. J Microencapsul 2004, 21:775-785.
49. Song X., Zhao Y., Wu W., Bi Y., Cai Z., Chen Q., et al. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int J Pharm 2008, 350:320-329.